News
ONC releases draft strategy on reducing EHR burden
Comments are sought to help drive direction of reforms.
Video
2018: A banner year for hematology drug approvals
SAN DIEGO – There have been 32 new hematology drug approvals and the year isn’t over yet.
News
Patient treatment expectations can outweigh equivocal effectiveness data
Article
Dermoscopy in family medicine: A primer
Dermoscopy allows you to see deeper into the skin than with the naked eye. Here’s how you can make use of it to spot malignant conditions sooner...
News
Phase 3 study confirms biosimilarity of PF-05280586 with rituximab
PF-05280586 showed biosimilarity to rituximab at up to 26 weeks in a randomized phase 3 study of treatment-naive patients with CD20-positive LTB-...
News
Factor IX expression stable at up to 8 years with gene therapy
SAN DIEGO – In severe hemophilia B, factor IX expression remains stable up to 8.6 years after scAAV2/8-LP1-hFIX–comediated gene therapy.
News
Similarity of CT-P6 and trastuzumab remain with longer follow-up
The efficacy and cardiac toxicity profile between trastuzumab biosimilar candidate CT-P6 and trastuzumab, as neoadjuvant and then adjuvant therapy...
News
PAD guidelines: Consensus needed between U.S. and Europe
News
CLL resistance mechanism to venetoclax identified
SAN DIEGO – The mutation was present only after therapy in paired samples from patients enrolled in clinical trials of venetoclax.
Video
KATHERINE: T-DM1 doubles HER2-positive invasive disease-free survival
SAN ANTONIO – For the primary endpoint of invasive disease-free survival, T-DM1 was associated with a hazard ratio of 0.50.